Prednisone News and Research

RSS

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced that Takeda has entered into a co-promotion agreement with Janssen Pharmaceutical K.K. for VELCADE® (bortezomib) for Injection, a treatment for patients with multiple myeloma.

10 May 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

CINJ researches identify new drug candidates that inhibits prostate cancer growth

Trying to break down a barrier that prevents effective treatment of prostate cancer, researchers from The Cancer Institute of New Jersey (CINJ) have identified candidate drugs that block a key protein responsible for tumor growth.

21 Apr 2010

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus.

20 Apr 2010

Women need to be educated on osteoporosis risk factors and treatment: Study

Underscoring what researchers call a serious global public health concern, results from a new study led by Columbia University Medical Center reveal that many women at an elevated level of risk for osteoporosis-associated fractures fail to perceive the implications of the risk factors.

8 Apr 2010

$Women unaware of risk of dangerous osteoporosis fractures$

Women unaware of risk of dangerous osteoporosis fractures

Only one in three Australian women diagnosed with osteoporosis are aware they are at higher risk of sustaining debilitating bone fractures, according to a landmark international study published with input from University of Sydney researchers.

7 Apr 2010

Study highlights need for public education on osteoporosis risk factors and treatment

Underscoring what researchers call a serious international public health concern, results from the Global Longitudinal Study of Osteoporosis in Women (GLOW) showed that among women at an elevated level of risk for osteoporosis-associated fractures, there is a failure to perceive the implications of having important risk factors.

3 Apr 2010

Study shows that steroids target hemangioma stem cells

Hemangiomas -- strawberry-like birthmarks that commonly develop in early infancy - are generally harmless, but up to 10 percent cause tissue distortion or destruction and sometimes obstruction of vision or breathing. Since the 1960s, problematic hemangiomas have been treated with corticosteroids such as dexamethasone or prednisone.

19 Mar 2010

Genentech announces topline results from Phase III trial of Avastin

Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).

12 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

$Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer$

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Sanofi-aventis announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.

3 Mar 2010

Step-up treatments may benefit children with asthma on low-dose inhaled corticosteroids

Children with asthma who continue to have symptoms while using low-dose inhaled corticosteroids could benefit from increasing the dosage or adding one of two asthma drugs, a new study by researchers at Washington University School of Medicine and other institutions finds.

3 Mar 2010

Parents often recognize signs of asthma in their children but delay home treatment: Report

Parents of young children with asthma often recognize signs that their child is about to have an asthma attack but delay home treatment until the attack occurs, researchers at Washington University School of Medicine in St. Louis report.

12 Feb 2010

Ulcerative colitis drug market to grow up to $2.1 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug market will nearly double from $1.2 billion in 2008 to $2.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

12 Feb 2010

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

5 Feb 2010

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

Robarts Clinical Trials at The University of Western Ontario in London, Canada, has been awarded a 4.7 million dollar grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease.

5 Jan 2010

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

AHS annual meeting focuses on myeloma, says IMF

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians— says a large number of abstracts – nearly a quarter of the presentations submitted this year to the annual meeting of the American Society of Hematology (ASH) were for myeloma, with one being presented at the prestigious plenary session.

9 Dec 2009